While the Gut Is Busy Repairing Wounds, Cancerous Cells May Also Seize the Opportunity to Expand

Why chronic intestinal inflammation develops into cancer years later may depend not only on which mutations cells accumulate, but also on the kind of “neighborhood” in which the mutated cells reside. A mouse study published in *Nature Genetics* indicates that the local environments formed as the intestine repairs inflammatory damage may make it easier for cell clones with oncogenic advantages to expand, gradually reshaping the competitive landscape between normal tissue and tumors.

The research team integrated in vivo lineage tracing, computer modeling, mutation analysis, and spatial transcriptomics to track the fate of cell clones in chronic colitis. The results showed that persistent inflammation creates patches in the colon that favor crypt fission and tissue repair; when clones with greater proliferative capacity enter these regions, their expansion can accelerate further. This means that “repair” may not merely be a phenomenon accompanying cancer after it develops, but could be a selective force before tumor initiation.

To place genetic mutations back in their original tissue locations, the researchers collected 288 biopsy samples, each 2 millimeters in diameter, from regions adjacent to the spatial transcriptomics sections and sequenced 22 genes associated with inflammatory bowel disease or colitis-associated cancer. The detected variants included the cancer driver genes Trp53, Kras, and Smad4, as well as genes related to the IL-17 pathway and chromatin remodeling. This made it possible to compare whether different mutant clones preferentially appeared in reparative, immune-enriched, or inflammation-signal-insensitive tissue neighborhoods.

The spatial analysis mapped multiple epithelial and immune cell environments. Regions displaying a fetal-like repair gene-expression program and marked by Trop2 were positively correlated with tumor burden and neutrophil-enriched regions; the more Trop2-positive tissue present, the more tumors were detected. Based on these findings, the study proposes that the expansion of repairing epithelial cells, together with the oxidative stress and genomic instability that neutrophils may cause, jointly creates an environment more favorable for oncogenic clones to gain prominence. However, these associations alone cannot yet demonstrate that neutrophils directly drive malignant transformation.

The study also presents another possible evolutionary path: some clones with anti-inflammatory advantages, such as those with Arid1a loss of function, were more frequently found in neighborhoods with weak responses to immune signals and were negatively correlated with tumors and repair regions. Staining of a small number of human colitis-associated cancer tissue samples likewise found that Arid1a-deficient epithelium can be spatially separated from tumors. This suggests that chronic inflammation may not drive malignant transformation in only one direction; different tissue environments may separately select for anti-inflammatory or cancer-promoting clones, and the two do not have the same effects on disease trajectory.

This work is still based primarily on Muc2-deficient, chemically induced mutagenesis, and other experimental mouse models. It cannot be used to directly infer cancer risk in human patients, nor has it demonstrated that Trop2 repair regions can serve as a clinical predictive marker. Its value lies in connecting mutations, cell states, and spatial locations into a mechanistic map. The next step will require long-term and prospective validation in more human inflammatory bowel disease tissues to determine which reparative neighborhoods truly appear before precancerous lesions and whether intervening in these environments can reduce malignant transformation without impairing necessary mucosal healing.